MedElevator
Войти в исследования American journal of ophthalmology · 2025
Ocular Comorbidities of Psoriasis: A Systematic Review and Meta-analysis of Observational Studies.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Ching-Ya, Lin Tzu-Yi, Wang Tzu-Yu, Chi Ching-Chi
Аннотация
TOPIC: Ocular comorbidities of psoriasis: A systematic review and meta-analysis of observational studies.
DESIGN: Systematic review and meta-analysis.
CLINICAL RELEVANCE: Ocular comorbidities of psoriasis have been raised with growing evidence. Certain eye diseases require prompt diagnosis and appropriate interventions, otherwise irreversible blindness may occur.
METHODS: We searched PubMed, MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) databases from their respective inception to August 15, 2025. Observational studies providing data on risk estimates for eye diseases, such as cataract, uveitis, dry eye disease, glaucoma, retinal vein occlusion, conjunctivitis, meibomian gland dysfunction and blepharitis, between patients with psoriasis and without psoriasis were included. Newcastle-Ottawa scale was utilized to evaluate the risk of bias. A random-effects model meta-analysis was conducted. Our primary outcomes were the risk estimates of ocular comorbidities in patients with psoriasis. This study is registered in the Open Science Framework (https://osf.io/tkn92).
RESULTS: We included 34 studies involving 10 045 036 subjects. Patients with psoriasis showed increased risk of cataract (hazard ratio [HR] 1.78, 95% confidence interval [CI] 1.53-2.07), uveitis (HR: 1.65, 95% CI: 1.35-2.01 [cohort studies]; odds ratio [OR] 2.56, 95% CI: 1.60-4.10 [case-control studies]), dry eye disease (OR: 5.01, 95% CI: 2.31-10.86), glaucoma (HR: 1.40, 95% CI: 1.05-1.88), retinal vein occlusion (HR: 1.58, 95% CI: 1.23-2.03), conjunctivitis (OR: 3.76, 95% CI: 1.33-10.63), meibomian gland dysfunction (OR: 4.45, 95% CI: 1.9-10.40), and blepharitis (OR: 2.28, 95% CI: 1.24-4.19).
CONCLUSIONS: The current evidence reveals associations of psoriasis with cataract, uveitis, dry eye disease, glaucoma, retinal vein occlusion, conjunctivitis, meibomian gland dysfunction and blepharitis. Ophthalmic consultation should be sought for psoriasis patients presenting ocular symptoms for prompt diagnosis and appropriate intervention.
DESIGN: Systematic review and meta-analysis.
CLINICAL RELEVANCE: Ocular comorbidities of psoriasis have been raised with growing evidence. Certain eye diseases require prompt diagnosis and appropriate interventions, otherwise irreversible blindness may occur.
METHODS: We searched PubMed, MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL) databases from their respective inception to August 15, 2025. Observational studies providing data on risk estimates for eye diseases, such as cataract, uveitis, dry eye disease, glaucoma, retinal vein occlusion, conjunctivitis, meibomian gland dysfunction and blepharitis, between patients with psoriasis and without psoriasis were included. Newcastle-Ottawa scale was utilized to evaluate the risk of bias. A random-effects model meta-analysis was conducted. Our primary outcomes were the risk estimates of ocular comorbidities in patients with psoriasis. This study is registered in the Open Science Framework (https://osf.io/tkn92).
RESULTS: We included 34 studies involving 10 045 036 subjects. Patients with psoriasis showed increased risk of cataract (hazard ratio [HR] 1.78, 95% confidence interval [CI] 1.53-2.07), uveitis (HR: 1.65, 95% CI: 1.35-2.01 [cohort studies]; odds ratio [OR] 2.56, 95% CI: 1.60-4.10 [case-control studies]), dry eye disease (OR: 5.01, 95% CI: 2.31-10.86), glaucoma (HR: 1.40, 95% CI: 1.05-1.88), retinal vein occlusion (HR: 1.58, 95% CI: 1.23-2.03), conjunctivitis (OR: 3.76, 95% CI: 1.33-10.63), meibomian gland dysfunction (OR: 4.45, 95% CI: 1.9-10.40), and blepharitis (OR: 2.28, 95% CI: 1.24-4.19).
CONCLUSIONS: The current evidence reveals associations of psoriasis with cataract, uveitis, dry eye disease, glaucoma, retinal vein occlusion, conjunctivitis, meibomian gland dysfunction and blepharitis. Ophthalmic consultation should be sought for psoriasis patients presenting ocular symptoms for prompt diagnosis and appropriate intervention.